<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071328</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00078508</org_study_id>
    <nct_id>NCT03071328</nct_id>
  </id_info>
  <brief_title>INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers</brief_title>
  <official_title>INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to plan for future clinical trials in patients with metastatic&#xD;
      urological cancers. Diluted iodinated contrast will be injected intra-tumorally under CT&#xD;
      fluoroscopy guidance into bone, lymph node, soft tissue and liver metastases in subjects with&#xD;
      metastatic prostate cancer, urothelial carcinoma, or renal cell carcinoma. Pre- and&#xD;
      post-injection CT images will be obtained to determine the injection parameters needed for&#xD;
      optimal distribution throughout metastases of a given size. A biopsy of the metastatic site&#xD;
      will also be obtained to validate expression of the receptor CD155.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of iodinated contrast enhancement within the metastasis on post-injection CT</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of iodinated contrast enhancement within the metastasis on post-injection CT</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of tumor CD155 membrane expression in metastatic bone, liver, soft tissue or lymph node specimens.</measure>
    <time_frame>Day 1</time_frame>
    <description>IHC will be used to assess tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens.</measure>
    <time_frame>Day 1</time_frame>
    <description>IHC will be used to assess tumor CD155 membrane expression in metastatic bone, liver, soft tissue, or lymph node specimens.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer (mCRPC)</condition>
  <condition>Metastatic Urothelial Carcinoma</condition>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Bone metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymph node metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Soft tissue metastatic site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isovue-M 200</intervention_name>
    <description>Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.</description>
    <arm_group_label>Bone metastatic site</arm_group_label>
    <arm_group_label>Liver metastatic site</arm_group_label>
    <arm_group_label>Lymph node metastatic site</arm_group_label>
    <arm_group_label>Soft tissue metastatic site</arm_group_label>
    <other_name>iodinated contrast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of adenocarcinoma of the prostate, renal cell&#xD;
             carcinoma or urothelial carcinoma. Small cell or neuroendocrine tumors of the prostate&#xD;
             are also permitted.&#xD;
&#xD;
          2. Radiographic evidence of at least one bone, lymph node, soft tissue, or liver&#xD;
             metastasis, that is amenable to iodinated contrast injection, as judged by the study&#xD;
             radiologist&#xD;
&#xD;
          3. Adequate laboratory values:&#xD;
&#xD;
               1. Platelets ≥ 100,000&#xD;
&#xD;
               2. INR ≤ 1.3&#xD;
&#xD;
          4. Age &gt; 18 years.&#xD;
&#xD;
          5. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of intercurrent or past medical or psychiatric illness that would make&#xD;
             participation in a research biopsy protocol difficult or not feasible at the&#xD;
             discretion of the principal investigator or co-investigator(s).&#xD;
&#xD;
          2. Cr &gt;2.0&#xD;
&#xD;
          3. History of iodinated contrast allergy&#xD;
&#xD;
          4. For patients undergoing research only biopsy: Requirement for anticoagulation with&#xD;
             heparin, low molecular weight heparin, clopidogrel, rivaroxaban, dabigatran, apixaban,&#xD;
             warfarin, Aggrenox, fondaparux, ticagrelor, etc (aspirin and other NSAIDs are ok but&#xD;
             should be held prior to biopsy in accordance with institutional standard of care)&#xD;
&#xD;
          5. Any other contraindication to CT with iodinated contrast, as CT with contrast will be&#xD;
             used in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan McNamara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Rasmussen, MS, RN, BSN</last_name>
    <phone>919-681-1030</phone>
    <email>julia.rasmussen@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Hurrelbrink, BA, BSN, RN</last_name>
      <phone>919-681-1030</phone>
      <email>julia.hurrelbrink@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Megan McNamara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

